Ventracor

Ventracor was a global medical device company focused on developing and commercializing implantable blood pumps, particularly the VentrAssist® left ventricular assist device (LVAD). This device was designed to support patients with end-stage heart failure, improving their survival and quality of life while they awaited heart transplants or were ineligible for transplantation. Founded with a vision to innovate in cardiac assist technology, Ventracor invested significantly in research and development, raising around $200 million over a decade. The company conducted clinical trials under the supervision of the U.S. Food and Drug Administration (FDA), showing promising results with a one-year survival rate of 74% for patients using the VentrAssist® LVAD. Ventracor primarily targeted surgeons and hospitals specializing in cardiac care in Australia and the United States.

• Employees 18
• Founded 1998